ABOUT US

History

> ABOUT US > History

  • 2020

    • 03 Planning to launch CLIA services in the US
  • 2019

    • 10 Contracted antibody development project with US Thermofisher
    • 10 Officially entered Japan after marketing contract with Japanese CMIC
    • 06 Contracted with domestic company W for PDX CTC analysis project
  • 2018

    • 11 Listed on KOSDAQ
    • 09 Contracted CTC analysis for anti cancer drug
    • 08 Contracted CTC analysis project with Samsung Seoul Hospital
    • 08 Contracted CTC analysis project with domestic company C pharmaceutical company
    • 06 Contracted CTC analysis project with Yonsei Severence Hospital
    • 05 Head office relocated to (Beobwon-ro, Songpa-gu, Seoul)
    • 03 Contracted CTC analysis project with Seoul St. Mary's Hospital
    • 02 4th contract with Daiichi Sankyo
  • 2017

    • 12 Signed platform supply contract with Samsung Seoul Hospital
    • 09 Contracted with National Cancer Center and ABL Bio to discover biomarkers
    • 07 Selected as a Future growth power flagship project by Ministry of Science & Technology (Awarded by Minister of science and ICT)
    • 06 3rd contract with Daiichi Sankyo
      Contracted CTC analysis project with Seoul St. Mary's Hospital
    • 05 Opened local Bio Polis office in Singapore
    • 05 Contracted Treatment Effectiveness Project with Seoul St. Mary's Hospital
    • 03 GMP certified for in vitro diagnostic medical reagents
      Approval of Isolation Kit in US
      Contracted with ABL BIO for anticancer drug efficacy verification project
  • 2016

    • 12 INNOBIZ certified by the Ministry of SME
      2nd contract with with Daiichi Sankyo
    • 11 Selected as an Industrial convergence leading company
    • 10 Selected as a Post genome genetic project by Ministry of Commerce, Industry and Energy, Korea
    • 07 Approval of IF Stainer/Time Laps Incubator in US, Japan
      Approval of Cell Image Analyzer in Japan
      First contract with Daiichi Sankyo
    • 06 Approval of IF Stainer/ Cell Image Analyzer/ Time Laps Incubator in Korea
    • 05 Approval of Cell Isolator in China
    • 04 Approval of Cell isolator in Korea and Japan
    • 04 Approval of medical device manufacturing from the department of Ministry of Health, Labor and Welfare, Japan
    • 03 GMP certified of in vitro diagnostic devices
    • 03 Approval of cell isolator in Europe
    • 02 ISO 13485 certified/ approval of Cell Isolator in the US
  • 2015

    • 09 Established CytoGen, Inc., USA (Silicon-Valley in the US)
  • 2014

    • 02 Approval of medical device manufacturing and cell separation chip manufacturing by Ministry of Food and Drug Administration
  • 2013

    • 10 Selected as a project of strengthening new growing power equipment with competitiveness by Ministry of Commerce, Industry and Energy
    • 06 Selected as an Advanced (Convergence) Technology Center (ACT) project by the Ministry of Commerce, Industry and Energy
    • 06 Selected as a Technological innovation development project by the ministry of small and medium sized enterprise
  • 2011

    • 10 Selected as a First-step component material technology development project
    • 10 Started commercial service related to CTC isolations
    • 06 Selected as a SME of convergence technology development project
    • 01 Registered as a Genetic Testing laboratory
  • 2010

    • 09 Established R&D center
    • 08 Application and approval by IRB, initiating clinical services
    • 06 Certified as a Venture enterprise
    • 03 Established CytoGen, Inc.
  • 2008

    • 01 Designed unique CTC Chips and confirmed reproducibility of CTC isolation using the chip
  • 2006

    • 01 R&D on pre/ post-processes for CTC isolations